A recent unique case report described clinical improvement in a patient with myxofibrosarcoma harboring a RAF1 S259P mutation and CDKN2A/Bloss who was treated with a combination of the MEK inhibitor trametinib and the CDK4/6 inhibitor palbociclib. This evidence concerns the gene CDKN2A and myxofibrosarcoma.